Drug Search Results
More Filters [+]

AL-1211

Alternative Names: AL-1211, AL1211, AL 1211
Latest Update: 2023-07-28
Latest Update Note: Clinical Trial Update

Product Description

AL1211 is a glucosylceramide synthase (GCS) inhibitor with unique and superior properties to other GCS inhibitors currently approved or in development. AL1211 is more potent and has a better off-target activity profile than other GCS inhibitors. AL1211 also has excellent penetration into the tissues that are affected in Fabry disease like heart and kidney. Importantly, AL1211 has low brain penetration, which maximizes the treatment of peripheral organs without concern for negative effects in the brain. (Sourced from: https://acelinktherapeutics.com/al1211/)

Mechanisms of Action: GCS Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: AceLink Therapeutics
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for AL-1211

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Fabry Disease

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events